Having "already achieved important milestones" in a first deal with Gubra ApS signed less than two years ago, Boehringer Ingelheim GmbH has entered into a second obesity collaboration with the Danish biotech.
The partners are teaming up again to develop poly-agonist peptides to treat obesity and concomitant diseases, saying that the collaboration will bring together Gubra’s knowledge in the design, synthesis, pharmaceutical characterization and in vivo testing of therapeutic peptides with BI’s R&D expertise in cardiometabolic disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?